PHE’s Baumgardner to Present on CAR-T Therapy Outcomes at ASH
Senior Research Economist James Baumgardner will be presenting “CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments” at the American Society of Hematology (ASH) 60thAnnual Meeting and Exposition, taking place from December 1-4 in San Diego, CA.
In the presentation, Dr. Baumgardner will share evidence on the past 10 to 20 years of anti-cancer innovation in terms of outcomes — measured by incremental quality-adjusted life years (QALYs) -– and in terms of cost effectiveness -– measured by incremental cost per QALY. The presentation will demonstrate how novel CAR-T therapy appears to break from previous trends.
For more information on ASH, or Dr. Baumgardner’s presentation, please click here.
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.